IMTX
Immatics N.V.
$9.79
-3.83%
$1.4B
No data for this timeframe.
Vol
Market Cap$1.4B
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (94%)
SEC Reports6
Press Releases6
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·Inc. P7·CIK 0001809196·Prev Close $10.18
Recent Activity
Jun 2, 2026
SEC
Immatics N.V. filed a 6-K on June 2, 2026, convening its Annual General Meeting (AGM) scheduled for June 18, 2026. The A
6-K — Impact 3/10
Jun 1, 2026
SEC
Immatics N.V. filed a 6-K on June 1, 2026, reporting updated Phase 1 clinical data for three pipeline candidates present
6-K — Impact 7/10
Jun 1, 2026
Press
Immatics reports extended Phase 1b data for anzu-cel (PRAME TCR T-cell therapy) in metastatic melanoma at ASCO 2026, sho
Impact 6/10
Jun 1, 2026
announcement
Immatics Presents Clinical Activity and Response Dynamics of Anzu-cel PRAME Cell Therapy at 2026 ASCO Annual Meeting
<p align="justify"><b>Houston, Texas and Tuebingen, Germany</b><b>, June 1, 2026 </b>– <a href="http
May 31, 2026
Press
Immatics presented extended Phase 1 data for its TCR bispecific IMA401 at ASCO 2026, showing a 29% confirmed ORR and 64%
Impact 6/10
May 12, 2026
SEC
Immatics reported Q1 2026 financial results showing a net loss of €57.8 million ($66.5 million) on revenue of €7.6 milli
6-K — Impact 6/10
Price Targets
$18.78
+91.8% upside
Strong Buy
Current $9.79
Low $12.20
Median $18.00
High $25.00
8 analysts
$12.20
$25.00
Analyst Ratings
7Strong Buy
10Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 19, 2026 | Chardan Capital | MAINTAIN | Buy → Buy |
| Apr 28, 2026 | TD Cowen | INITIATE | Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.48 | $-0.55 — $-0.34 | 29% YoY | 8 |
| Next Q | $-0.50 | $-0.59 — $-0.36 | -2% YoY | 8 |
| Current FY | $-1.95 | $-2.22 — $-1.24 | -4% YoY | 9 |
| Next FY | $-1.89 | $-2.36 — $-1.40 | 3% YoY | 9 |
Latest Reports
NEUTRAL
6-K
3/10
Immatics N.V. filed a 6-K on June 2, 2026, convening its Annual General Meeting (AGM) scheduled for June 18, 2026. The A
Jun 2, 2026
BULLISH
6-K
7/10
Immatics N.V. filed a 6-K on June 1, 2026, reporting updated Phase 1 clinical data for three pipeline candidates present
Jun 1, 2026
BULLISH
Press
6/10
Immatics reports extended Phase 1b data for anzu-cel (PRAME TCR T-cell therapy) in metastatic melanoma at ASCO 2026, sho
Jun 1, 2026
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
6 SEC filing reports analyzed. Sentiment: 3 bullish, 1 bearish, 1 mixed, 1 neutral. Avg impact: 6.2/10.
NEUTRAL
6-K
3/10
Immatics N.V. filed a 6-K on June 2, 2026, convening its Annual General Meeting (AGM) scheduled for
Jun 2, 2026
BULLISH
6-K
7/10
Immatics N.V. filed a 6-K on June 1, 2026, reporting updated Phase 1 clinical data for three pipelin
Jun 1, 2026
BEARISH
6-K
6/10
Immatics reported Q1 2026 financial results showing a net loss of €57.8 million ($66.5 million) on r
May 12, 2026
MIXED
PRESS-RELEASE
6/10
Immatics reported Q1 2026 EPS of -$0.29, a 33.9% beat vs consensus of -$0.44, but revenue fell sharp
May 12, 2026
BULLISH
6-K
7/10
Immatics announced that four abstracts from its clinical programs will be presented as oral presenta
Apr 21, 2026
BULLISH
6-K
8/10
Immatics announced a deep and durable remission in a pediatric patient with advanced metastatic neph
Apr 17, 2026
BULLISH
6/10
Immatics reports extended Phase 1b data for anzu-cel (PRAME TCR T-cell therapy) in metastatic melano
Jun 1, 2026
BULLISH
6/10
Immatics presented extended Phase 1 data for its TCR bispecific IMA401 at ASCO 2026, showing a 29% c
May 31, 2026
BULLISH
7/10
Immatics reported updated Phase 1 data for IMA203CD8 PRAME cell therapy at ASCO 2026, showing 63% OR
May 30, 2026
BULLISH
7/10
Immatics announced that four of its abstracts have been accepted for oral presentation at the 2026 A
Apr 21, 2026
BULLISH
7/10
Immatics announced a deep and ongoing remission in a 17-year-old pediatric patient with advanced nep
Apr 17, 2026
NEUTRAL
5/10
Immatics reported full-year 2025 financial results with a significant revenue decline to $56.8 milli
Mar 5, 2026
Current analyst consensus: Strong Buy (94% buy). Based on 18 analysts: 7 strong buy, 10 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$18.78 mean target
+91.8% upside
Strong Buy (1.00)
$12.20 Low
$25.00 High
| Metric | Value |
|---|---|
| Current Price | $9.79 |
| Target Low | $12.20 |
| Target Mean | $18.78 |
| Target Median | $18.00 |
| Target High | $25.00 |
| # Analysts | 8 |
| Recommendation | Strong Buy (1.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.48 | $-0.55 | $-0.34 | 28.6% | — | 3↑ 5↓ | $0.0B | 123.5% | 8 |
| Next Q 2026-09-30 |
$-0.50 | $-0.59 | $-0.36 | -2.0% | — | 4↑ 4↓ | $0.0B | 93.8% | 8 |
| Current FY 2026-12-31 |
$-1.95 | $-2.22 | $-1.24 | -3.9% | — | 2↑ 7↓ | $0.0B | -18.2% | 9 |
| Next FY 2027-12-31 |
$-1.89 | $-2.36 | $-1.40 | 2.7% | — | 2↑ 7↓ | $0.1B | 10.3% | 9 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.483 | |
| 7d ago | $-0.483 | +0.000 |
| 30d ago | $0.000 | -0.483 |
| 60d ago | $-0.459 | -0.024 |
| 90d ago | $-0.502 | +0.019 |
2 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 19, 2026 | Chardan Capital | MAINTAIN | Buy | Buy |
| Apr 28, 2026 | TD Cowen | INITIATE | — | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 7 | 10 | 1 | 0 | 0 | 94% | |
| May 1, 2026 | 7 | 10 | 1 | 0 | 0 | 94% | |
| Apr 1, 2026 | 7 | 9 | 1 | 0 | 0 | 94% | |
| Mar 1, 2026 | 7 | 9 | 1 | 0 | 0 | 94% | |
| Feb 1, 2026 | 7 | 9 | 1 | 0 | 0 | 94% | |
| Jan 1, 2026 | 7 | 9 | 1 | 0 | 0 | 94% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 1, 2026
announcement
Immatics Presents Clinical Activity and Response Dynamics of Anzu-cel PRAME Cell Therapy at 2026 ASCO Annual Meeting
<p align="justify"><b>Houston, Texas and Tuebingen, Germany</b><b>, June 1, 2026 </b>– <a href="https://www.globenewswire.com/Tracker?data=lEEf82PPB3W
May 31, 2026
announcement
Immatics Presents Data on IMA401 MAGEA4/8 Bispecific at 2026 ASCO Annual Meeting with Simultaneous Publication in Nature Medicine Supporting Development of IMA401/IMA402 Combination in Lung Cancer
<p align="justify"><b>Houston, Texas and Tuebingen</b><b>, Germany,</b><b> May 31, 2026 </b>– <a href="https://www.globenewswire.com/Tracker?data=ry-h
May 30, 2026
announcement
Immatics Presents Clinical Activity of IMA203CD8 PRAME Cell Therapy in Hard-to-Treat Gynecologic Cancers at 2026 ASCO Annual Meeting
<p align="justify"><b>Houston, Texas and Tuebingen, Germany, May 30, 2026 </b>– <a href="https://www.globenewswire.com/Tracker?data=a4xbhiPrYVkKWvo1d7
May 12, 2026
earnings
Immatics Announces First Quarter 2026 Financial Results and Business Update
<p align="justify"><b>Houston, Texas and Tuebingen, Germany, May 12, 2026 </b>– <a href="https://www.globenewswire.com/Tracker?data=ERq4AXkGlpyt9DvPzI
May 11, 2026
earnings_calendar
IMTX Q1 2026 Earnings Scheduled — 2026-05-11
Apr 21, 2026
announcement
Immatics Announces Four Upcoming Oral Presentations Across Its Clinical Cell Therapy and Bispecific Portfolio at 2026 ASCO Annual Meeting
<p><b>Houston, Texas and Tuebingen, Germany, April 21, 2026 </b>– <a href="https://www.globenewswire.com/Tracker?data=mZwOm1yTMLXdR7Z3O1-khiPUu-k2uscG
Apr 17, 2026
announcement
PRAME-directed Cell Therapy Using Immatics’ TCR Induces Deep and Durable Remission in Pediatric Patient with Advanced Metastatic Nephroblastoma
<p align="justify"><b>Houston, Texas and Tuebingen, Germany, April 17, 2026 </b>– <a href="https://www.globenewswire.com/Tracker?data=--TjRLbafXT_Ez-4
Mar 5, 2026
earnings
Immatics Announces Full Year 2025 Financial Results and Business Update
<p align="justify"><b>Houston, Texas and Tuebingen, Germany, March 5, 2026 </b>– <a href="https://www.globenewswire.com/Tracker?data=NpO-94nogMIKmJeAU